Clinical Trials · NCT03353350
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Enrollment
- 406
- Start date
- Dec 2017
- Locations
- 54 sites, 5 countries
- Primary endpoint
- Change in Glycated Hemoglobin (HbA1c) (%)